Y[east]{.smallcaps} cells grow by budding, a specialized form of cell division. Bud emergence occurs in the G1 phase of the cell cycle at predictable locations on the cell surface. Several proteins required for bud emergence, including actin and the rho-type GTPase, Cdc42p ([@B1]; [@B58]), assemble at this site. Subsequently, the actin cytoskeleton is polarized towards this site, which leads to polarized secretion, cell surface growth, and formation of a bud ([@B52]; [@B12]; [@B1]; [@B34]). Cytokinesis later occurs at the position of bud emergence, resulting in a mother and a daughter cell. Thus, when cells choose bud sites, they fix the orientation of the actin cytoskeleton, the polarity of secretion, and the position for cytokinesis.

The position of bud assembly is specified by a set of bud-site selection genes and by cell type ([@B24]; [@B5]; [@B8]; [@B10]; [@B54]; [@B56]). **a** and α cells choose sites in an axial pattern, in which cells bud adjacent to the previous division site. **a**/α cells choose bipolar sites, in which daughter cells (cells that have not budded previously) typically bud distal to the previous division site; mother cells (cells that have budded previously) choose sites proximal or distal to the previous division site ([@B14]; [@B9]). The ability of cells to exhibit predictable budding patterns suggests that intracellular landmarks direct the position of bud emergence ([@B8]; [@B48]). The behavior of two classes of mutants is consistent with this landmark hypothesis. Mutations in *BUD3*, *BUD4*, *AXL1*, or *AXL2/BUD10* disrupt the axial budding pattern, but have no effect on the bipolar budding pattern of **a**/α cells ([@B8]; [@B10]; [@B15]; [@B21]; [@B40]). In contrast, mutations in *BNI1*, *SPA2*, *PEA2*, *BUD6*, *BUD7*, *BUD8*, or *BUD9* disrupt the bipolar budding pattern, but have no effect on the axial budding pattern of **a** and α cells ([@B54]; [@B56]; [@B3]). The first set of genes is specifically required for the axial budding pattern, whereas the second set is specifically required for the bipolar budding pattern.

For cells budding in the axial pattern, the bud site used in one cell cycle specifies an adjacent position for bud emergence in the next cell cycle ([@B9]). Bud3p, Bud4p, and Axl2/Bud10p are located in a cortical position at the mother-bud neck from mitosis of one cell cycle to G1 of the next ([@B11]; [@B21]; [@B40]; [@B45]). Thus, during G1, Bud3p, Bud4p, and Axl2/Bud10p behave as spatial remnants of the position of bud emergence in the previous cell cycle and promote adjacent bud emergence in the new cell cycle. These cortical factors are proposed to organize the cytoskeleton by recruiting downstream proteins required for bud emergence, such as Cdc24p and Bem1p, to that site ([@B47]; [@B6]). Indeed, Rsr1p/Bud1p, required for both axial and bipolar budding, binds to bud emergence proteins Cdc24p and Bem1p ([@B57]; [@B36]), and Bud6p interacts with actin in the yeast two-hybrid assay ([@B2], [@B3]).

Axl2/Bud10p is a type I integral membrane protein that is thought to provide spatial information for the axial pattern ([@B21]; [@B40]). It traverses the secretory pathway to reach its final destination at the plasma membrane and contains N-linked oligosaccharides. Axl2/Bud10 has a receptor-like topology: a single transmembrane domain and substantial intra- and extracellular domains. The large NH~2~-terminal domain is extracellular, rich in serine and threonine residues, and is postulated to interact with the cell wall. During G1, Axl2/Bud10p is present first at the presumptive bud site and later at the periphery of the bud. As the bud grows, Axl2/Bud10p is found in an apparent ring structure on the bud side of the mother-bud neck. It later forms an additional apparent ring on the mother side of the mother-bud neck during mitosis. Initial localization of Axl2/Bud10p to the neck requires septin proteins ([@B40]). Subsequent organization of Axl2/Bud10p into rings at the neck requires Bud3p ([@B21]).

In the present study, we describe a requirement for O-glycosylation in bud-site selection. Yeast has seven protein mannosyl transferases (pmt)^1^, encoded by *PMT* genes, that catalyze the initial step of O-linked glycosylation ([@B51]; [@B18]). These enzymes transfer a mannosyl residue from a dolichol-phosphate donor onto serine or threonine residues of substrate proteins in the endoplasmic reticulum ([@B22]; [@B49]; [@B25]; [@B28]; [@B18]). Further modification of these O-linked oligosaccharides occurs in the Golgi apparatus ([@B22]; [@B23]). Pmts are required for cell wall integrity, cell morphology, and coordination of the nuclear and morphological cell cycles ([@B18]). We show here that mutations in the mannosyl transferase gene *PMT4* affect the axial budding pattern of **a** and α cells. The requirement of Pmt4p for bud-site selection appears to result from its O-linked glycosylation of Axl2/Bud10p.

Materials and Methods {#MaterialsMethods}
=====================

Materials
---------

HA11 mAb, used to detect the hemagglutinin epitope (HA) in an Axl2/ Bud10p-HA fusion protein, was from Berkeley Antibody Company. Polylysine, protease inhibitors (phenylmethylsulfonyl fluoride, benzamidine, antipain, leupeptin, and pepstatin), calcofluor white, and protein standards were from Sigma Chemical Co. HRP-coupled sheep anti--mouse antibodies were from Nycomed Amersham, Inc. Peptide N-glycosidase F (PNGase) and tunicamycin were from Boehringer Mannheim Corp.

Microbiological and Molecular Biological Methods
------------------------------------------------

Strains are described in Table [I](#TI){ref-type="table"}, and plasmids in Table [II](#TII){ref-type="table"}. DNA and yeast genetic manipulations were performed as described ([@B4]; [@B44]; [@B42]). Synthetic low ammonium histidine dextrose (SLAHD) solid medium for assaying pseudohyphal growth was prepared as described by [@B20]. Microcolony budding assays were performed as previously described ([@B8]; [@B45]).

Isolation of Axial-defective Mutants
------------------------------------

### Construction of SY77.

The *HMR**a*** gene of IH2531 (α *ura3-52*) was disrupted by introduction of pDR58 digested with EcoRV ([@B27]), creating SY77. The disruption was confirmed by Southern blot analysis.

### Mutagenesis.

A culture of SY77 was grown to saturation in rich medium, resuspended in water, and UV-irradiated in separate aliquots to 0.3--24% survival. Mutagenized cells were plated on solid SLAHD medium to induce pseudohyphal growth ([@B20]) and incubated at 30°C for 2 wk in the dark. Of ∼70,000 surviving colonies, 407 exhibited the pseudohyphal colony morphology. Microcolony budding assays were performed on the 107 colonies that retested for pseudohyphal growth. 23 of these mutants exhibited \>30% bipolar budding and were studied further.

### Genetic Tests.

Mutants were tested for single-gene segregation by analyzing the budding pattern of the meiotic progeny of crosses to IH2393 (**a** Bud^+^). Mutants whose progeny exhibited 2:2 axial/bipolar budding were studied further. Because **a**/α strains do not exhibit the axial budding pattern, dominance or recessiveness was assessed by analyzing *mat**a**1/MAT*α diploid progeny (phenotypically α) formed by crosses between the mutants and a *mat**a**1* strain (IH1785). Recessive mutations yielded an axial budding pattern in the *mat**a**1/MAT*α diploids; dominant or semidominant mutations yielded a bipolar or partially bipolar phenotype. Mutants defective in known genes required for axial budding were identified by complementation tests using plasmids carrying *BUD3*, *BUD4*, or *AXL1*, by mating to *bud3*, *bud4*, *axl1*, or *axl2* strains, and, for new *BUD4* and *AXL1* alleles, by linkage tests. Complementation tests among the mutants were performed by analyzing diploids (phenotypically α) formed by crossing *mat**a**1* and α mutant strains. If the resultant diploid exhibited axial budding, the two mutations were assigned to different complementation groups. If the resultant diploid exhibited bipolar budding, the two mutations were assigned to the same complementation group.

Cloning BAD15/PMT4
------------------

The bud-site selection axial determinant *BAD15/PMT4* gene was cloned by complementation of the pseudohyphal growth phenotype. SY167 (α *bad15-1 ura3*) was transformed with a low copy yeast library marked with *URA3* ([@B41]). Approximately 10,200 transformants were patched onto SLAHD plates in two concentric rings of 25 (because the pseudohyphal phenotype in **a** and α cells was sensitive to position on the plate, as well as the number of colonies per plate). Plates were incubated for 2 wk at 30°C and scored for pseudohyphae by microscopic examination at 30×. Nine transformant colonies failed to exhibit pseudohyphal growth and were assayed for budding pattern. Plasmid DNA isolated from the three colonies that exhibited axial budding contained overlapping inserts by restriction analysis.

Complete Deletion of PMT4
-------------------------

The *pmt4*Δ constructs replaced the entire *PMT4* coding sequence with the *LEU2* or *TRP1* gene. The HindIII--SalI fragment of pSS47, which contains *PMT4* and YJR142W, was cloned into the vector pBluescript (Stratagene), creating pSS48. All sequences of pSS48, except the *PMT4* open reading frame (ORF), were amplified using PCR with divergent primers (OSS8 5′-CCGaggcctCTTTTTCTGTTCACTAACCACAAACGAACTG and OSS9 5′-CCGaggcctCTGTACTTCTGTGGACTGTCAGAAAATATCTTGG; a StuI restriction site is denoted in lower case) that hybridized just upstream of the *PMT4* start codon and downstream of the stop codon. The resulting linear fragment was cleaved at the introduced StuI sites and circularized, yielding a plasmid (pSS49) that contained the *PMT4* flanking regions separated by the StuI site. The *LEU2* gene was then introduced into the StuI site to form pSS51, with the direction of *LEU2* transcription opposite that of *PMT4*. The resulting disruption fragment was excised from pSS51 by digestion with HindIII and SphI and used to replace the chromosomal *PMT4* gene by one-step gene replacement ([@B43]). The presence of the *pmt4* deletion was confirmed by colony PCR with the following oligonucleotides: OSS10, derived from *LEU2*: 5′-TTAGACCGCTCGGCCAAACAACC; and OSS11, derived from the *PMT4* 3′ sequences not present in the pSS49 plasmid, 5′-GGCCATACCATGAAGTATACC; amplified a ∼0.8-kB fragment in *pmt4*:: *LEU2* cells. Control oligonucleotides: OSS7, derived from the *PMT4* 3′ flanking sequences, 5′-CCGAGGCCTCTGTACTTCTGTGGACTGTCAGAAAATATCTTGG; and OSS11 amplified a ∼0.5-kB fragment in Pmt^+^ cells. To create a *pmt4*::*TRP1* allele, the HincII--StuI fragment of YPP14, containing *TRP1*, was introduced into the StuI site of pSS49. The resultant plasmid, pSS52, was digested with ClaI and SphI and used to disrupt the chromosomal copy of *PMT4* by one-step gene replacement ([@B43]). The presence of the *pmt4* deletion was confirmed by analyzing bud-site selection pattern.

Membrane Extracts and Western Blot Analysis
-------------------------------------------

Yeast cells grown overnight and harvested in log phase were washed with 50 mM Tris-HCl, pH 7.5, 50 mM MgCl~2~, 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, and disrupted with glass beads in the same buffer containing 20 μg/ml antipain, 1 μg/ml leupeptin, and 1 μg/ml pepstatin. The cell wall fraction was removed by centrifugation at 1,500 *g*. The resulting supernatant was centrifuged at 48,000 *g* to generate a membrane pellet. 5 to 10 μg of membrane protein was subjected to SDS-PAGE using 8 or 10% SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose membranes, blocked in TBS containing 0.1% Tween 20 and 4% nonfat dry milk, and decorated with a 1:1,000 dilution of HA antibodies in TBS containing 0.1% Tween 20 and 1% nonfat dry milk. Axl2/Bud10p-HA was visualized using the Nycomed Amersham ECL protein detection kit.

Peptide N-Glycosidase F Treatment
---------------------------------

Membrane pellets were resuspended in 1% SDS, 1% β-mercaptoethanol, 35 mM EDTA, and heated to 95°C for 3 min. 10 vol of incubation buffer (50 mM potassium phosphate buffer, pH 6.8, 35 mM EDTA, 1% β-mercaptoethanol, 0.55% octyl glucoside) was added, followed by a second incubation at 95°C for 3 min. Protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 20 μg/ml antipain, 1 μg/ml leupeptin, and 1 μg/ml pepstatin) were added, and the reaction mixture was divided into two parts. PNGase was added to one aliquot, and both reaction mixtures were incubated at 37°C for 12 to 16 h.

Hydrogen Fluoride Treatment
---------------------------

O- and N-linked sugars were removed by anhydrous hydrogen fluoride (HF) cleavage ([@B32]). Membrane fractions (50 μg protein) were lyophilized and dried in a desiccator containing solid P~2~O~5~. 250 μl HF was added and samples were treated for 80 min at 0°C. HF was subsequently removed by evaporation in a nitrogen stream.

Tunicamycin Treatment
---------------------

Yeast cells were grown overnight to early log phase, harvested, resuspended in fresh medium, and grown for 30 min at 30°C. Tunicamycin (10 μg/ml) was added, cells were incubated at 30°C for 60 min, and then subjected to membrane extraction as described in Membrane Extracts and Western Blot Analysis.

Microscopy
----------

To observe the autofluorescence of a fusion protein containing Axl2/ Bud10p and green fluorescent protein (GFP), cells in log phase were mounted on 0.5% agarose pads under coverslips sealed with pink or red nail polish. To observe bud scars, cells were stained with calcofluor as described by [@B37]. Cells were visualized using a Zeiss Axioplan microscope with the FITC filter set and photographed with a three-chip cooled CCD camera.

Results {#Results}
=======

Use of the Pseudohyphal Phenotype to Isolate Bud-site Selection Mutants
-----------------------------------------------------------------------

To identify genes required specifically for the axial budding pattern, we searched for mutants of α cells that exhibited a bipolar, rather than axial, budding pattern. This screening method took advantage of the relationship between pseudohyphal growth and budding pattern. Pseudohyphal growth is exhibited by cells with a bipolar budding pattern, such as **a**/α cells ([@B20]), as well as **a** *bud4* and α *bud4* mutants in the Σ1278b strain background ([@B45]). In contrast, cells that bud in the axial pattern, such as α strain SY77 (α *ura3-52 hmr**a***::*URA3*), do not exhibit pseudohyphal growth. We screened ∼70,000 colonies derived from UV-irradiated SY77 cells for the pseudohyphal growth phenotype. Budding patterns of the 107 mutants that displayed the pseudohyphal phenotype were assayed using a microcolony assay (see Materials and Methods). Ten *BAD* mutants exhibited bipolar budding patterns upon retesting and were shown to be defective in single genes by segregation analysis (see Materials and Methods). Of these, four were defective in *BUD4*, one was defective in *BUD3*, and one in *AXL1* ([@B8]; [@B15]). Complementation tests revealed that the four remaining mutants, *bad15*, *bad43*, *bad54*, and *bad85*, defined three additional complementation groups. We show here that the complementation group identified by *bad15* and *bad43* corresponds to the previously identified gene *PMT4*.

bad15 Mutants Have a Daughter-specific Defect in Bud-site Selection
-------------------------------------------------------------------

*bad15* mutant cells exhibited a novel budding pattern that is neither axial nor bipolar (Table [III](#TIII){ref-type="table"}, line 3). In the axial pattern, cells bud adjacent to the previous division site ([@B9]; Table [III](#TIII){ref-type="table"}, lines 1 and 7). In the bipolar pattern, daughter cells typically bud distal to the previous division site, whereas mother cells bud either near the division site or distal to the previous division site ([@B9]; Table [III](#TIII){ref-type="table"}, lines 2 and 6). *bad15* mutants (and to a lesser extent, *bad43* mutants) exhibited a distinctive, unipolar budding pattern in which daughter cells budded distal to the division site, as in the bipolar pattern, and mother cells exhibited a typical axial pattern, budding adjacent to the previous division site (Table [III](#TIII){ref-type="table"}, lines 3 and 5). The similar phenotypes of *bad15* and *bad43* mutants suggested that they might be defective in the same gene. Indeed, these mutants failed to complement (Table [III](#TIII){ref-type="table"}, line 9). To determine whether the *bad15* mutation affected bipolar budding, **a**/α *bad15/bad15* diploids were constructed and analyzed. These strains exhibited normal bipolar budding (Table [III](#TIII){ref-type="table"}, compare lines 2 and 4). These data indicated that the *bad15* mutation affected only the axial budding pattern and primarily the behavior of daughter cells. This conclusion was supported by observing the budding patterns of *bad15* cells over several generations. In one experiment in which eleven separate pedigrees were followed, 38/39 *bad15* mother cells budded towards the previous division site, whereas 27/28 *bad15* daughter cells budded away from the previous division site. Nine daughter cells in this experiment divided to become mother cells that divided again. In all cases, these cells budded towards the previous division site in the next cell cycle when they became mothers. These data demonstrated that the *bad15* budding defect was exhibited only by daughter cells and not by mother cells.

To determine whether *bad15* mother cells exhibited normal axial budding, bud scars were analyzed by calcofluor staining. Since *bad15* is an allele of *PMT4* (see below), a complete deletion of *PMT4* was used for this study. Cells with a single bud or bud scar and a visible birth scar were scored. Consistent with the microcolony data, which suggest that daughter cells budded incorrectly, only 29% of *pmt4* cells placed the first bud or bud scar adjacent to the birth scar. Rather, 66% of *pmt4* cells placed the first bud or bud scar opposite the birth scar (*n* = 100), as is typical of the first bud in the bipolar pattern ([@B9]). In contrast, 94% of wild-type (WT) cells positioned a bud or bud scar adjacent to the birth scar (*n* = 100), as is typical of the axial budding pattern ([@B9]). However, after the initial incorrect bud-site selection event, *pmt4* mother cells budded in an axial pattern (Fig. [1](#F1){ref-type="fig"}, top, compare *PMT4* to *pmt4*::*LEU2*). 99% of the bud scars in both WT and *pmt4* cells with two bud scars or a bud and a bud scar were adjacent (*n* = 100 in both cases), as is typical of the axial budding pattern ([@B9]). In addition, 96% of the bud scars in WT and 92% of the bud scars in *pmt4* cells with three or more scars were adjacent (*n* = 300). The calcofluor staining pattern of WT and *pmt4* cells with three or more bud scars was indistinguishable, suggesting that *pmt4* cells bud axially after an initial incorrect bud-site selection choice.

bad15 Mutants Are Defective in the PMT4 Gene
--------------------------------------------

The *BAD15* gene was cloned by screening for reversal of the pseudohyphal behavior of *bad15* strain SY167. Only subclones containing the *PMT4* gene were able to complement the bud-site selection defect of *bad15* mutants (Fig. [2](#F2){ref-type="fig"}; Table [IV](#TIV){ref-type="table"}, lines 1--4). Pmt4p is one of seven yeast enzymes that initiate addition of O-linked oligosaccharides to proteins ([@B18]). *BAD15* was confirmed to be allelic to *PMT4* from the following experiments. First, *pmt4* mutants failed to complement the bud-site selection defect of *bad15* mutants, although both *pmt4* and *bad15* mutations were recessive (Table [IV](#TIV){ref-type="table"}, lines 5, 6 and 7). Second, the same spectrum of proteins underglycosylated in *pmt4* mutants was underglycosylated in *bad15* and *bad43* mutants (data not shown). Third, the bud-site selection phenotype of strains with mutations in *PMT4* was identical to that of *bad15* and *bad43* mutants: all exhibited an axial budding defect that was daughter-specific, resulting in unipolar, rather than axial or bipolar budding (Table [V](#TV){ref-type="table"}, lines 8--13). Fourth, *BAD15* and *PMT4* exhibited tight genetic linkage: only two axial-budding recombinants were found in 13 tetrads (52 segregants) in crosses between α *bad15* (SY167) and ***a** pmt4*::*LEU2* (SY450).

The seven yeast pmt enzymes have different substrate specificities: for example, O-glycosylation of Bar1p and Cts1p is severely affected by mutations in *PMT1* and *PMT2*, but not by mutations in *PMT4*. In contrast, O-glycosylation of Kex2p and Gas1p/Gpg1p/gp115 is severely affected by mutations in *PMT4*, but not by mutations in *PMT1* and *PMT2* ([@B18], [@B19]). To determine if *PMT4* is unique among *PMT* genes in being required for normal budding pattern, mutants defective in each of the *PMT* genes were analyzed. Of the six *pmt* mutants tested, only *pmt4* mutants exhibited altered budding patterns (Table [V](#TV){ref-type="table"}, lines 1--7). The difference in penetrance of the *pmt4* phenotype in the experiments shown in Tables [III](#TIII){ref-type="table"} and [V](#TV){ref-type="table"} was due to differences in the strain backgrounds (data not shown).

Pmt4p Promotes Addition of O-linked Oligosaccharides to Axl2/Bud10p
-------------------------------------------------------------------

Since Pmt4p is a protein mannosyl transferase, we hypothesized that it was involved in O-glycosylation of a protein required for axial budding. Because PMT activity is confined to the ER, only proteins that pass through the ER can be glycosylated by these enzymes. Of all the proteins known to be involved in axial bud-site selection, only Axl2/Bud10p transits the secretory pathway ([@B40]) and thus, is a candidate for O-glycosylation. We have used an epitope-tagged allele, *AXL2/BUD10-HA*, which complements *axl2/bud10* mutations ([@B40]), to test whether Axl2/Bud10p is a substrate for Pmt4p.

Because a lack of O-linked sugars might cause a change in the apparent molecular weight of Axl2/Bud10p, its mobility in *pmt* mutants was examined by SDS-PAGE (Fig. [3](#F3){ref-type="fig"}). Full-length Axl2/Bud10p (∼205 kD) was found in all *pmt* mutants, with the exception of *pmt4* (Fig. [3](#F3){ref-type="fig"} A), in which smaller fragments (∼43--59 kD) accumulated. Since the predicted molecular weight of the Axl2/Bud10p ORF is ∼91 kD, these data indicated that Axl2/Bud10p had undergone proteolytic cleavage. These 43--59-kD fragments, found exclusively in the membrane fraction (M. Gentzsch and W. Tanner, unpublished data), apparently lacked N-linked oligosaccharides, as their mobility did not change after treatment with PNGase (Fig. [3](#F3){ref-type="fig"} B).

Fortuitously, studies of Axl2/Bud10p in the presence of tunicamycin revealed a stabilized form of the protein in *pmt4* cells (Fig. [4](#F4){ref-type="fig"} A). We do not understand the nature of this tunicamycin-induced stabilization. In the presence of tunicamycin, Axl2/Bud10p from WT cells migrated at ∼125 kD. The absence of fully glycosylated (∼205 kD) Axl2/Bud10p suggests that its half-life is short since all is cleared within the 60 min tunicamycin treatment. Axl2/ Bud10p from *pmt4* mutants migrated at ∼114 kD under the same conditions, indicating that Axl2/Bud10p in *pmt4* mutants lacked a posttranslational modification. The modification was characterized by subjecting the Axl2/Bud10p species from tunicamycin-treated WT and *pmt4* cells to treatment with HF to release remaining carbohydrates (O-linked sugars; Fig. [4](#F4){ref-type="fig"} B). HF treatment of WT extracts resulted in a further reduction in molecular weight of Axl2/Bud10p to ∼100 kD, indicating that it is an O-glycosylated protein (Fig. [4](#F4){ref-type="fig"} B, compare WT + HF to WT-HF). After treatment with HF, Axl2/Bud10p from *pmt4* cells comigrated with the Axl2/Bud10p from WT cells at ∼100 kD (Fig. [4](#F4){ref-type="fig"} B, compare + HF samples). The shift in SDS-PAGE mobility of the 114-kD form of Axl2/Bud10p from *pmt4* mutants indicated that it possessed some O-linked oligosaccharide (Fig. [4](#F4){ref-type="fig"} B, compare *pmt4* samples). These observations indicate that Axl2/Bud10p from *pmt4* mutants and from WT cells both contained O-linked oligosaccharides, but that Axl2/Bud10p received fewer O-linked oligosaccharides in *pmt4* cells than in WT cells. Axl2/Bud10p received ∼25 kD of O-linked oligosaccharides: ∼13 kD are Pmt4p-independent; the remainder are Pmt4p-dependent.

In contrast to its behavior in *pmt4* strains, Axl2/Bud10p from tunicamycin-treated *pmt1*, *pmt2*, *pmt3*, *pmt5*, and *pmt6* strains was almost indistinguishable in size from WT Axl2/Bud10p (Fig. [4](#F4){ref-type="fig"} A). Longer SDS-PAGE runs, which separated proteins of high molecular weight, showed that Axl2/Bud 10p was slightly smaller in *pmt1* and *pmt2* strains (data not shown). Addition of the Pmt4p-independent O-linked oligosaccharides present on Axl2/Bud10p in *pmt4* mutants may be added by Pmt1p and Pmt2p.

Degradation of Axl2/Bud10p Probably Occurs in the Golgi Apparatus
-----------------------------------------------------------------

To determine the subcellular compartment in which proteolysis of Axl2/Bud10p occurred in *pmt4* cells, Axl2/ Bud10p was analyzed in strains with temperature-sensitive mutations in *sec18* and *sec7*, which disrupt secretory traffic from the ER to the Golgi apparatus and through the Golgi apparatus, respectively ([@B35]). Axl2/Bud10p was degraded in *pmt4 sec18* cells grown at permissive temperature (Fig. [5](#F5){ref-type="fig"}, left, 25°C). Incubation of cells at 37°C resulted in accumulation of full-length, nondegraded Axl2/ Bud10p (Fig. [5](#F5){ref-type="fig"}, left, 37°C). In contrast, Axl2/Bud10p was degraded at both 25°C and 37°C in the *sec7 pmt4* strain (Fig. [5](#F5){ref-type="fig"}, right). These data suggested that degradation of Axl2/Bud10p occurred after the secretory block imposed by *sec18* and before the block imposed by *sec7*. Thus, degradation of Axl2/Bud10p most likely occurred in the Golgi apparatus.

If Axl2/Bud10p is degraded in the Golgi apparatus, its cleavage should be independent of vacuolar proteases. That prediction was borne out. Mutations in the genes encoding vacuolar proteases Pep4p, Prb1p, and Prc1p did not prevent degradation of full-length Axl2/Bud10p in *pmt4* mutants (Fig. [6](#F6){ref-type="fig"} A). Considerably more of the 43--59-kD Axl2/Bud10p species was found in *pmt4 pep4 prb1* and *pmt4 pep4 prb1 prc1* mutants than in *pmt4* mutants alone, suggesting that vacuolar proteases further degrade the 43-- 59-kD fragments. Degradation of Axl2/Bud10p in *pmt4* mutants was unaffected by mutation of *UBC7*, which encodes a ubiquitin-conjugating enzyme that participates in degradation of ER proteins ([@B7]), again suggesting that the cleavage of Axl2/Bud10p does not occur in the ER (Fig. [6](#F6){ref-type="fig"} B).

Axl2/Bud10p Is Improperly Localized in pmt4 Mutants
---------------------------------------------------

Localization of Axl2/Bud10p is dependent upon cell cycle stage ([@B21]; [@B40]). In early G1 cells, Axl2/Bud10p is found in a patch at the presumptive bud site; it is later found at the periphery of the bud. By the time of the G2/M transition, Axl2/Bud10p is observed on the bud side of the mother-bud neck and is subsequently found on both sides of the mother-bud neck. Axl2/ Bud10p persists at the neck region of mother and daughter cells past cytokinesis. We made similar observations in our Pmt^+^ strain background using cells that produce a fusion of Axl2/Bud10p to the GFP ([@B21]; Fig. [7](#F7){ref-type="fig"}, a--f). 97% of fluorescent WT cells in an asynchronous population exhibited strong staining that fell into one of three classes. Almost 50% of cells (202/407) exhibited staining at bud periphery (Fig. [7](#F7){ref-type="fig"}, a and b). 30% of cells (121/407) exhibited staining predominantly at the bud side of the mother-bud neck (Fig. [7](#F7){ref-type="fig"}, c and d). 17% exhibited strong staining that was symmetrically distributed with respect to the mother-bud neck (Fig. [7](#F7){ref-type="fig"}, e and f). Though we detected no difference in the distribution of cells with respect to the cell cycle in *pmt4* mutants versus WT cells, only 10% of *pmt4* cells (37/369) exhibited staining that fell into the three classes defined by WT cells. Most mutant cells exhibited a strikingly different localization pattern (Fig. [7](#F7){ref-type="fig"}, g--l): 58% (216/369) exhibited a punctate intracellular pattern (Fig. [7](#F7){ref-type="fig"}, g, h, i, k, and l) that resembled the Golgi apparatus ([@B13]; [@B38]). Such staining was seen in only 3% of Pmt^+^ cells. 13% of *pmt4* cells with these punctate intracellular patches also exhibited relatively normal staining at the bud periphery (28/216; Fig. [7](#F7){ref-type="fig"}, g \[right cell\] and h). Many *pmt4* cells (206/369) accumulated Axl2/Bud10p at the neck. However, unlike WT cells, the neck staining was enriched on, or was specific to, the mother side of the mother-bud neck (78/369 cells; Fig. [7](#F7){ref-type="fig"}, i and j) or faint, but equally distributed on either side of the neck (121/369 cells; Fig. [7](#F7){ref-type="fig"}, k and l). None of the neck staining in WT cells was observed in either of these two categories. Localization of the Bud4 protein was unaffected by mutation of *pmt4* (data not shown).

Overexpression of AXL2/BUD10 Partially Restores Axial Bud-site Selection to pmt4 Mutants
----------------------------------------------------------------------------------------

If Axl2/Bud10p activity is decreased due to the lack of O-linked oligosaccharides, overexpression of *AXL2/BUD10* might partially restore the axial budding pattern to *pmt4* mutants. To test this possibility, *pmt4* and WT strains were transformed with YEp24-*AXL2*, which carries *AXL2/ BUD10* on a high copy plasmid. This plasmid slightly decreased the axial budding of WT cells, from 93 to 76% axial. In contrast, YEp24-*AXL2* partially rescued the unipolar budding pattern of *pmt4* mutants to axial, increasing axial budding from 5 to 40%.

Discussion {#Discussion}
==========

Axl2/Bud10p is a transmembrane glycoprotein required for yeast cells to exhibit the axial budding pattern ([@B21]; [@B40]). Like Bud3p and Bud4p ([@B11]; [@B45]), it is proposed to function as an intracellular landmark: Axl2/ Bud10p localizes to both sides of the mother-bud neck for part of the cell cycle and is inherited by both mother and daughter cells at the position of bud emergence in the previous cell cycle. Through the isolation and characterization of mutants with altered bud-site selection, we have uncovered a requirement for O-linked glycosylation by the mannosyl transferase Pmt4p, which presumably acts directly on Axl2/Bud10p. Though O-linked glycosylation has been assumed to be important for protein function, identifying specific roles for this modification on particular proteins has been elusive. We suggest that O-linked glycosylation of Axl2/Bud10p promotes its movement through the secretory pathway, prevents its degradation, and allows Axl2/Bud10p to function on the cell surface to assemble components required for bud emergence.

O-linked Glycosylation by Pmt4p Enhances the Stability of Axl2/Bud10p
---------------------------------------------------------------------

Axl2/Bud10p acquires O-linked oligosaccharides, some of which are dependent upon Pmt4p. Only the Pmt4p-dependent sugars appear to be important for Axl2/Bud10p function. Because Axl2/Bud10p in *pmt4* mutants contains some O-linked oligosaccharide, it is clear that the simple presence of O-linked oligosaccharide is not sufficient to facilitate Axl2/Bud10p protein function. It appears that, as with protein phosphorylation, the amount of O-linked oligosaccharide or the specific sites of modification are important for function. Studies of Axl2/Bud10p provide an opportunity to identify the determinants for recognition by Pmt4p and other PMT proteins. Because proteins, such as Kex2p and Gas1p/gp115/Ggp1p are glycosylated primarily by Pmt4p ([@B19]), comparison of Kex2p, Gas1p/gp115/Ggp1p, and Axl2/Bud10p may help to identify consensus acceptor sequences for Pmt4p-dependent O-linked glycosylation. All three proteins have extracellular domains rich in serine and threonine residues that are close to the membrane ([@B30]; [@B53]; [@B21]; [@B40]). These domains are glycosylated in the case of Kex2p and Gas1p/ gp115/Ggp1p ([@B16]; [@B55]; [@B17]; [@B19]), and perhaps Axl2/Bud10p as well. Serine- and threonine-rich domains close to the membrane may be recognized specifically by Pmt4p.

Pmt4p is required for the stability of Axl2/Bud10p. Axl2/Bud10p is a large, type I integral protein of the plasma membrane. In *pmt4* mutants, Axl2/Bud10p is cleaved to produce stable membrane-associated fragments of ∼43--59 kD, which appear to be the cytoplasmic-transmembrane segment of Axl2/Bud10p. This structure is inferred from three lines of evidence. First, the fragments are recognized by antibodies specific for an epitope tag at the COOH terminus of Axl2/Bud10p. Second, as these fragments are membrane-associated, they presumably also contain the transmembrane domain. Third, these fragments lack both N- and O-linked oligosaccharides, which should be present solely in the extracellular domain. [@B40] determined that Axl2/Bud1p is a type I membrane protein by demonstrating that the COOH terminus of Axl2/Bud10p is refractory to degradation by proteases added extracellularly. The apparent molecular weight of the protease-resistant fragments (a collection of fragments 50--55 kD) is similar to that of the fragments we observe in *pmt4* mutants (43--59 kD), adding further credence to the notion that the fragments contain the COOH terminus of Axl2/Bud10p joined to the transmembrane domain. We do not know the fate of the remaining ∼40% of Axl2/Bud10p, which includes the NH~2~-terminal segment.

Two lines of evidence suggest that the initial degradation of Axl2/Bud10p in *pmt4* mutants occurs in the Golgi apparatus. First, proteolytic cleavage of Axl2/Bud10p occurs in *sec7 pmt4*, but not in *sec18 pmt4* mutants, suggesting that cleavage requires transit to the Golgi apparatus and occurs even when further transport is inhibited. Consistent with this notion, cleavage of Axl2/Bud10p to the ∼55-kD fragments does not require vacuolar proteases. The accumulation of these ∼55-kD fragments in *pep4 prb1* and *pep4 prb1 prc1* cells suggested that once generated, these fragments are degraded in the vacuole.

Previous studies have revealed an effect of O-glycosylation on protein stability. Axl2/Bud10p is stabilized in *pmt4* mutants grown in the presence of the N-linked glycosylation inhibitor, tunicamycin. We do not know the reason for this stabilization. One possibility is that in the absence of N-linked sugars, Axl2/Bud10p cannot reach the Golgi apparatus, where its initial degradation occurs. However, Axl2/Bud10p localization in *pmt4* mutants appears the same in the presence versus absence of tunicamycin (data not shown). We favor a second possibility, that the conformation of Axl2/Bud10p lacking its N-linked sugars makes it a poorer substrate for proteolytic degradation. Several proteins, including the low density lipoprotein (LDL) receptor, decay accelerating factor, major envelope protein of Epstein-Barr virus, Kex2p, and neurotrophin receptor are less stable when they lack O-linked oligosaccharides ([@B26]; [@B16]; [@B39]; [@B31]). Not all O-linked oligosaccharides are important for protein function, however: Gas1p/Ggp1p/gp115 and human chorionic gonadotropin lacking O-linked oligosaccharides ([@B29]; [@B17]) are indistinguishable in stability from their glycosylated counterparts.

Instability of Axl2/Bud10p and its failure to accumulate efficiently at the cell surface without modification by Pmt4p are probably coupled, though it is unclear which is the primary consequence of the O-glycosylation defect. Perhaps unmodified Axl2/Bud10p is recognized as a misfolded protein and targeted for destruction by a quality control system of the Golgi apparatus. Resulting proteolytic fragments might be inefficiently targeted to the plasma membrane. Another possibility is that absence of Pmt4p-dependent modifications delays movement of Axl2/ Bud10p through the secretory pathway, increasing the probability of cleavage by a resident Golgi protease. Some Axl2/Bud10p does assemble at the bud periphery and neck in *pmt4* cells, though the amount is reduced with respect to WT cells. As for the LDL receptor ([@B26]), the lack of O-linked oligosaccharide may also affect Axl2/Bud10p stability once it reaches the plasma membrane. Axl2/Bud10p seems to be inherently unstable.

PMT4 Is Required for Proper Budding Only in Daughter Cells
----------------------------------------------------------

Because cells defective in *PMT4* exhibit a bud-site selection defect, we initially predicted the existence of a Pmt4p substrate protein important for accurate budding. Our studies indicate that Axl2/Bud10p is the Pmt4p substrate relevant to bud-site selection: Axl2/Bud10p is O-glycosylated, unstable and mislocalized in *pmt4* mutants, and its overproduction can partially rescue the *pmt4* phenotype. The requirement for Pmt4p only in daughter cells might be explained in a variety of ways. In principle, Axl2/ Bud10p might be required only in daughter cells, or its glycosylation might be necessary only in daughter cells. Because Axl2/Bud10p is required for bud-site selection in both mother and daughter cells ([@B21]; [@B40]), the first explanation appears to be incorrect. Therefore, we entertain a second possibility, that O-linked glycosylation of Axl2/Bud10p by Pmt4p is required only in daughter cells. Perhaps O-glycosylation is not needed to stabilize Axl2/Bud10p in mother cells. This explanation is unlikely, since a single, partially degraded population of Axl2/Bud10p is detected by Western blot (Fig. [3](#F3){ref-type="fig"} A), and intracellular patches of Axl2/Bud10p accumulate in both mother and daughter cells (Fig. [7](#F7){ref-type="fig"}). Another possibility is that mother cells can accommodate the reduction of Axl2/Bud10p activity in *pmt4* mutants, whereas daughter cells cannot. We favor this third possibility.

The differences between mother and daughter cells in the requirement for *PMT4* may arise from differences in the path by which Axl2/Bud10p reaches the mother-bud neck (Fig. [8](#F8){ref-type="fig"}). Axl2/Bud10p is thought to become localized to the bud side of the mother-bud neck by reorganization of protein in cells with a small bud (Fig. [8](#F8){ref-type="fig"} A, 2 and 3). Localization of Axl2/Bud10p at the mother side of the mother-bud neck is hypothesized to occur subsequently by new synthesis within the mother cell ([@B40]; Fig. [8](#F8){ref-type="fig"} A, 3). After cytokinesis, both mother and daughter cells inherit a patch of Axl2/Bud10p, which promotes utilization of axial bud sites. In *pmt4* mutants, we propose that Axl2/Bud10p is at a reduced level, so that the activity in the daughter side of the mother-bud neck is inadequate (Fig. [8](#F8){ref-type="fig"} B). In contrast, newly synthesized Axl2/Bud10p, which becomes localized to the mother side of the mother-bud neck (Fig. [8](#F8){ref-type="fig"} B, 3), is proposed to be adequate for promoting utilization of axial bud sites after cytokinesis (Fig. [8](#F8){ref-type="fig"} B, 4). In other words, Axl2-Bud10p used for axial budding in daughter cells must persist from S phase until the next G1 phase, whereas that in mother cells need persist only from late mitosis until the next G1 phase. That daughter cells exhibit a longer G1 phase than do mother cells might also make it harder for Axl2/Bud10p to persist until it is needed again in daughter cells. Support for the proposal that Axl2-Bud10p is differentially affected in mother and daughter cell compartments comes from the observation that Axl2-Bud10p can be observed preferentially on the mother side of the mother-bud neck in a substantial fraction of *pmt4* mutant cells (21%), a distribution that is rare in WT cells (0.25%). For the 33% of *pmt4* cells that exhibited faint Axl2/Bud10p staining on both sides of the mother-bud neck, we argue that this level of Axl2/ Bud10p is sufficient for bud-site selection in mother cells, but is inadequate in daughter cells.

Several functional differences between mother and daughter cells have been described previously. Mother cells can switch mating type, whereas daughter cells cannot ([@B50]); mother cells specifically inherit plasmids containing autonomously replicating sequences (ARS) and lacking centromere sequences, whereas daughter cells do not ([@B33]); and mother cells budding in the bipolar pattern may bud distal or proximal to the birth site, whereas new daughter cells bud primarily at distal sites ([@B9]). O-glycosylated cell-surface molecules certainly contribute to selection of bud sites in **a**/α cells: both Bud8p and Bud9p appear to be O-glycosylated ([@B56]; N. Pagé, H. Bussey, J.R. Pringle, personal communication). Here, we have observed that the integrity of an O-glycosylated landmark protein can differentially affect the behavior of mother and daughter cells and generate an asymmetric cell division. Asymmetrically located landmarks that are anchored to the cell wall by O-glycosylated proteins might contribute to the asymmetric switching of mating type and plasmid inheritance as well.
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:   bud-site selection axial determinant

GFP

:   green fluorescent protein

HA

:   hemagglutinin epitope

HF

:   hydrogen fluoride

ORF

:   open reading frame

pmt

:   protein mannosyl transferase

PNGase

:   peptide N-glycosidase F

SLAHD

:   synthetic low ammonium histidine dextrose

WT

:   wild-type

###### 

Strains Used in this Study

  Strain                                        Genotype                                                                           Source
  ------------------------------------------ -- ------------------------------------------------------------------------------- -- -----------------------
  IH2531                                        α *ura3-52*                                                                        [@B20]
  SY96[\*](#TFI-150){ref-type="table-fn"}       α *ura3-52*                                                                        Fink Laboratory
  SY77[\*](#TFI-150){ref-type="table-fn"}       α *hmr**a***::*URA3*                                                               This study
  SY167[\*](#TFI-150){ref-type="table-fn"}      α *bad15 ura3*                                                                     This study
  SY172[\*](#TFI-150){ref-type="table-fn"}      α *bad43 ura3*                                                                     This study
  SY171[\*](#TFI-150){ref-type="table-fn"}      α *bud4-3*                                                                         This study
  SY202                                         ***a***/α *bad15/bad15 ura3/*+ *his4/*+ *trp1/*+ (isogenic with SY204)             This study
  SY204                                         ***a***/*α ura3*/+ *his4*/+ *trp1*/+ (isogenic with SY202)                         This study
  MY16[\*](#TFI-150){ref-type="table-fn"}       α *leu2 ura3-52*                                                                   M. Maxon, IH Lab
  SY448[\*](#TFI-150){ref-type="table-fn"}      α *leu2 pmt4*::*LEU2*                                                              This study
  MY13[\*](#TFI-150){ref-type="table-fn"}       ***a*** *leu2*                                                                     M. Maxon, IH Lab
  SY447[\*](#TFI-150){ref-type="table-fn"}      ***a*** *leu2 pmt4*::*LEU2*                                                        This study
  SY463                                         ***a***/α *leu2/leu2*                                                              This study
  SY464                                         ***a***/α *pmt4*::*LEU2/pmt4*::*LEU2 leu2/leu2*                                    This study
  SY414                                         α *leu2-3 ura3-52 his3-*Δ*200 lys2-801 trp1-*Δ*901 suc2-*Δ*9*                      Tanner Lab Collection
  SY655[‡](#TFI-152){ref-type="table-fn"}       α *pmt1*::*URA3*                                                                   Tanner Lab Collection
  SY656[‡](#TFI-152){ref-type="table-fn"}       α *pmt2*::*LEU2*                                                                   Tanner Lab Collection
  SY657[‡](#TFI-152){ref-type="table-fn"}       α *pmt3*::*HIS3*                                                                   Tanner Lab Collection
  SY415[‡](#TFI-152){ref-type="table-fn"}       α *pmt4*::*TRP1*                                                                   Tanner Lab Collection
  SY658[‡](#TFI-152){ref-type="table-fn"}       α *pmt5*::*URA3*                                                                   Tanner Lab Collection
  SY659[‡](#TFI-152){ref-type="table-fn"}       α *pmt6*::*URA3*                                                                   Tanner Lab Collection
  IH1783                                        ***a*** *trpl leu2 ura3 his4 can1*                                                 IH Lab Collection
  SY450[§](#TFI-153){ref-type="table-fn"}       ***a*** *pmt4*::*LEU2*                                                             This study
  SY748[§](#TFI-153){ref-type="table-fn"}       *mat*::URA3 pmt4::LEU2                                                             This study
  IH1785[§](#TFI-153){ref-type="table-fn"}      *mat**a**l-50*                                                                     IH Lab Collection
  SY221                                         *mat**a**l-50 bad15 his4 leu2 ura3*                                                This study
  MGY60[‡](#TFI-152){ref-type="table-fn"}       α *axl2*::*AXL2-HA*                                                                This study
  MGY61[‡](#TFI-152){ref-type="table-fn"}       α *pmt1*::*HIS3 axl2*::*AXL2-HA*                                                   This study
  MGY62[‡](#TFI-152){ref-type="table-fn"}       α *pmt2*::*LEU2 axl2*::*AXL2-HA*                                                   This study
  MGY63[‡](#TFI-152){ref-type="table-fn"}       α *pmt3*::*HIS3 axl2*::*AXL2-HA*                                                   This study
  MGY64[‡](#TFI-152){ref-type="table-fn"}       α *pmt4*::*TRP1 axl2*::*AXL2-HA*                                                   This study
  MGY65[‡](#TFI-152){ref-type="table-fn"}       α *pmt5*::*URA3 axl2*::*AXL2-HA*                                                   This study
  MGY66[‡](#TFI-152){ref-type="table-fn"}       α *pmt6*::*LYS2 axl2*::*AXL2-HA*                                                   This study
  YWO333                                        α *ade2-1^o^ his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100*                         Dieter Wolf
  YWO339[‖](#TFI-155){ref-type="table-fn"}      ***a*** *pep4*Δ::*HIS3 prb1*::*LEU2*                                               Dieter Wolf
  YWO340[‖](#TFI-155){ref-type="table-fn"}      ***a*** *pep4*Δ::*HIS3 prb1*::*hisG prc1*::*hisG*                                  Dieter Wolf
  MGY69[‖](#TFI-155){ref-type="table-fn"}       α *axl2*::*AXL2-HA*                                                                This study
  MGY70[‖](#TFI-155){ref-type="table-fn"}       ***a*** *pep4*Δ::*HIS3 prb1*::*LEU2 axl2*::*AXL2-HA*                               This study
  MGY71[‖](#TFI-155){ref-type="table-fn"}       ***a*** *pep4*Δ::*HIS3 prb1*::*hisG prc1*::*hisG axl2*::*AXL2-HA*                  This study
  MGY72[‖](#TFI-155){ref-type="table-fn"}       α *pmt4*Δ::*TRP1 axl2*::*AXL2-HA*                                                  This study
  MGY73[‖](#TFI-155){ref-type="table-fn"}       ***a*** *pmt4*::*TRP1 pep4*Δ::*HIS3 prb1*::*LEU2, axl2*::*AXL2-HA*                 This study
  MGY74[‖](#TFI-155){ref-type="table-fn"}       ***a*** *pmt4*::*TRP1 pep4*::*HIS3 prb1*::*hisG prc1*::*hisG axl2*::*AXL2-HA*      This study
  MGY67[‡](#TFI-152){ref-type="table-fn"}       α *axl2*::*AXL2-HA ubc7*::*LEU2*                                                   This study
  MGY68[‡](#TFI-152){ref-type="table-fn"}       α *pmt4*::*TRP1 axl2*::*AXL2-HA ubc7*::*LEU2*                                      This study
  MGY75 [¶](#TFI-154){ref-type="table-fn"}      *axl2*::AXL2-HA                                                                    This study
  MGY76 [¶](#TFI-154){ref-type="table-fn"}      α *ura3-52 leu2-3,112 suc2-*Δ*9 sec7axl2*::*AXL2-HA pmt4*::*LEU2*                  This study
  MGY77[†](#TFI-151){ref-type="table-fn"}       *axl2*::AXL2-HA                                                                    This study
  MGY78[†](#TFI-151){ref-type="table-fn"}       α *ura3-52 leu2-3,112 suc2-*Δ*9 sec18axl2*::*AXL2-HA pmt4*::*LEU2*                 This study

 Isogenic to IH2531, except where noted.  

 Isogenic to SY414, except where noted.  

 Isogenic to IH1783, except where noted.  

 Isogenic to YWO333, except where noted.  

Isogenic to SEY5018, except where noted.  

 Isogenic to SEY5188, except where noted.  

###### 

Plasmids Used in this Study

  Plasmid           Description                                                                                        Source
  -------------- -- ----------------------------------------------------------------------------------------------- -- -----------------------------------
  pDR58             *hmra*::*URA3* knock-out construct                                                                 D. Rivier, University of Illinois
  pSS51             *pmt4*::*LEU2* knock-out construct                                                                 This study
  pSS52             *pmt4*::*TRP1* knock-out construct                                                                 This study
  pAH14             *AXLBUD10-*GFP in pRS314                                                                           [@B21]
  pRS314            CEN ARS vector containing *TRP1*                                                                   [@B46]
  p*AXL2-HA*        Encodes *AXL2-HA*; inYIp5                                                                          [@B40]
  YEp24-*AXL2*      *2*μ *AXL2*                                                                                        [@B40]
  B1,B5,B7,B9       Original *bad15* complementing clones in YCp50 containing ORFs YJR140C-YJR147W                     This study; [@B41]
  pSS44             B7 lacking the ∼4.5 kB SphI fragment (one SphI site was from the plasmid vector),                  This study
                     contains ORFs YJR140C-YJR143C (*PMT4*)                                                            
  pSS45             ClaI-HpaI fragment of B7 cloned into the ClaI-NruI sites of Ycp50,                                 This study
                     contains all of YJR142W and a portion of YJR143C (*PMT4*)                                         
  pSS46             EcoRI-BglII fragment of pSS44 in the EcoRI-BamHI sites of YCp50,                                   This study
                     contains all of YJR140C, YJR141W, and a portion of YJR142W                                        
  pSS47             pSS44 lacking the HindIII fragment, contains all of ORFs YJR142W and YFR143C (*PMT4*)              This study
  pSS48             HindIII-SalI fragment of pSS47 cloned into the HindIII-SalI sites of pBluescript (Stratagene)      This study
  pSS49             pSS48 lacking the *PMT4* ORF (see Materials and Methods)                                           This study

###### 

Mutants Defective in bad15 Display a Daughter-specific Defect in Bud-site Selection

                                           \% Class I      \% Class II                 \% Class III               
  ------------------------------------- -- ------------ -- ------------------------ -- -------------- -- ----- -- -----
  1\. α *BAD15*                            98               1                          \<1               \<1      200
  2\. ***a***/α *BAD15/BAD15*               7              33                          53                7        600
  3\. α *bad15*                            21              71                           5                4        300
  4\. ***a***/α *bad15/bad15*               9              20                          63                8        300
  5\. α *bad43*                            22              51                          21                6        100
  6\. α *bud4*                             10              27                          40                24       300
                                                                                                                  
  Relevant genotype                        \% Class I      \% Classes II, III, IV                                 
  7\. ***a*** *1* ^−^/α *bad15/+*          93               7                          100                        
  8\. ***a*** *1* ^−^/α *bad15/bad15*      15              85                          100                        
  9\. ***a*** *1* ^−^/α *bad43/bad15*      12              88                          100                        

Budding pattern was determined by analyzing the morphology of microcolonies (see Materials and Methods). Class I, axial pattern, mother and daughter cells budded adjacent to the previous division site; Class II, mother cells budded near the previous division site, daughter cells budded distal to the previous division site; Class III, both mother and daughter cells budded distal to the previous division site; Class IV, all other microcolony morphologies. Class II and III together represent the bipolar budding pattern. The mother cell is drawn on the left. Strains used were: SY77, line 1; SY204, line 2; SY167, line 3; SY202, line 4; SY172, line 5; SY171, line 6; SY221 × IH2531, line 7; SY221 × SY167, line 8; and SY221 × SY172, line 9.  

![*bad15/pmt4* mother cells bud in an axial pattern. WT cells (IH1783, *PMT4*) or cells lacking the *BAD15/PMT4* gene (SY450, *pmt4*::*LEU2*) were stained with calcofluor. Cells with two bud scars (top) or ≥3 bud scars (bottom) were counted and photographed.](JCB9902007.f1){#F1}

![The budding pattern defect of the *bad15* mutant is complemented by plasmids containing *PMT4*. SY167 cells (α *bad15*) were transformed with the indicated plasmids. A, B7; B, pSS44; C, pSS45; D, pSS47; E, pSS46. Black lines indicate DNA present in the clones. Arrows indicate the direction of transcription of individual ORFs. 1, YJR140C; 2, YJR141W; 3, YJR142W; 4, YJR144W; 5, YJR145C; 6, YJR146W; 7, YJR147W. Budding pattern of the transformants was scored using a microcolony assay (Materials and Methods).](JCB9902007.f2){#F2}

###### 

bad15 Mutants Are Defective in PMT4 Activity

  Relevant genotype                             Plasmid      \% Class I      \% Classes II, III, IV      *n*
  ------------------------------------------ -- --------- -- ------------ -- ------------------------ -- -----
  1\. *BAD15*                                   YCp50        80              20                          200
  2\. *BAD15*                                   *PMT4*       79              21                          100
  3\. *bad15*                                   YCp50         7              93                          171
  4\. *bad15*                                   *PMT4*       76              24                          301
  5\. *mat*::*URA3*/α *pmt4*::*LEU2/bad15*      none         25              75                          300
  6\. ***a*** *1* ^−^/α *bad15/BAD15*           none         92               8                          300
  7\. *mat*::*URA3*/α *pmt4*::*LEU2/PMT4*       none         97               3                          300

Budding pattern was determined by analyzing the morphology of microcolonies as described in the legend to Table [III](#TIII){ref-type="table"} (see also Materials and Methods). Strains used were: IH2531, lines 1 and 2; SY167, lines 3 and 4; SY748 × SY167, line 5; IH1785 × SY167, line 6; and SY748 × SY96, line 7.  

###### 

Mutants Defective in PMT4, but Not other PMT Genes, Have Altered Budding Patterns

  Relevant genotype                               \% Class I      \% Class II      \% Classes III & IV      n
  -------------------------------------------- -- ------------ -- ------------- -- --------------------- -- -----
   1. Pmt^+^                                      93               7               *\<*1                    200
   2. *pmt1*                                      90               5               5                        200
   3. *pmt2*                                      97               2               1                        200
   4. *pmt3*                                      91               6               3                        200
   5. *pmt4*                                      59              38               3                        200
   6. *pmt5*                                      92               6               2                        200
   7. *pmt6*                                      90               8               2                        116
   8. ***a*** Pmt^+^                              96               2               2                        200
   9. ***a*** *pmt4*::*LEU2*                       5              86               9                        200
  10\. α Pmt^+^                                   96               3               1                        155
  11\. α *pmt4*::*LEU2*                           13              77               10                       179
  12\. ***a***/α Pmt^+^                           16              27               57                       200
  13\. ***a***/α *pmt4*::*LEU2/pmt4*::*LEU2*       1              43               56                       600

Budding pattern was determined by analyzing the morphology of microcolonies as described in the legend to Table [III](#TIII){ref-type="table"} (see also Materials and Methods). Strains used were: SY414, line 1; SY655, line 2; SY656, line 3; SY657, line 4; SY415, line 5; SY658, line 6; SY659, line 7; MY13, line 8; SY447, line 9; MY16, line 10; SY448, line 11; SY463, line 12; and SY464, line 13.  

![Axl2/Bud10p in *pmt4* mutants is degraded, membrane-associated, and lacks N-linked sugars. (A) Membrane extracts were prepared from WT (MGY60) and *pmt* mutant cells (MGY61-66) producing AXL2-HA (Material and Methods). Extracts were separated by SDS-PAGE and visualized by immunoblotting using anti-HA antibodies. (B) Extracts from WT (MGY60) and a *pmt4* mutant (MGY64) were treated with PNGase. Samples were separated by SDS-PAGE and visualized by immunoblotting.](JCB9902007.f3){#F3}

![Axl2/Bud10p is stabilized in *pmt4* cells treated with tunicamycin and is incompletely O-glycosylated. (A) WT (MGY60) and *pmt* mutant cells (MGY61-66) were treated with tunicamycin (Materials and Methods). Membrane extracts were prepared, separated by SDS-PAGE, and visualized by immunoblotting. (B) Membranes of tunicamycin-treated WT (MGY60) and *pmt4* cells (MGY64) were subjected to further deglycosylation by treatment with HF. Samples were separated by SDS-PAGE and visualized by immunoblotting.](JCB9902007.f4){#F4}

![Degradation of Axl2/Bud10p in *pmt4* mutants occurs in the Golgi apparatus. Mutant strains, *pmt4 sec18* (MGY78) and *pmt4 sec7* (MGY76), were grown at the permissive temperature (25°C) or at 37°C to induce the secretory block. Membrane extracts were prepared, separated by SDS-PAGE, and visualized by immunoblotting.](JCB9902007.f5){#F5}

![Initial cleavage of Axl2/Bud10p in *pmt4* mutants does not depend on vacuolar proteases or the ER-linked proteolytic system. (A) Membrane extracts were prepared, separated by SDS-PAGE, and visualized by immunoblotting from *PMT4* or *pmt4* cells possessing (MGY69 or MGY72) or lacking (MGY70, 71, 73, 74) vacuolar proteases Pep4, Prb1p, and Prc1p. (B) Membrane extracts were prepared, separated by SDS-PAGE, and visualized by immunoblotting from *PMT4* or *pmt4* cells possessing (MGY69 or MGY72) or lacking (MGY67 or 68) ubiquitin conjugating enzyme Ubc7p.](JCB9902007.f6){#F6}

![Axl2/Bud10p is improperly localized in *pmt4* mutants. IH1783 cells (*PMT4*, a--f) or SY450 cells (*pmt4*::*LEU2*, g--l) carried pAH14, a low-copy plasmid encoding Axl2/Bud10p-GFP. Cells were grown to early log phase, sonicated, and visualized by fluorescence microscopy.](JCB9902007.f7){#F7}

![The daughter cell-specific budding pattern phenotype of *pmt4* mutants may be explained by reduced activity of Axl2/Bud10p in both mother and daughter cells. (A) WT cells. 1, Axl2/Bud10p (black crescent) is localized at the periphery of a WT bud. 2, Axl2/ Bud10p is reorganized to the bud side of the mother-bud neck. 3, New synthesis of Axl2/ Bud10p leads to its accumulation on the mother side of the mother-bud neck. 4, After cytokinesis, both mother and daughter cells inherit a patch of Axl2/Bud10p. The mother cell initiates bud formation adjacent to the residual patch of Axl2/ Bud10p. 5, The daughter cell initiates bud formation adjacent to the residual patch of Axl2/ Bud10p. The residual patches of Axl2/Bud10p disappear (hatched rectangles). (B) *pmt4* cells: 1, Axl2/Bud10p (black crescent) is localized at the periphery of a *pmt4* mutant bud. Axl2/Bud10p is also found in punctate intracellular patches (black circles). 2, Axl2/Bud10p is reorganized to the bud side of the mother-bud neck. The reduced accumulation of Axl2/Bud10p to the bud neck is represented by the small size of the black rectangle (compare to A 2). 3, New synthesis of Axl2/Bud10p leads to its accumulation on the mother side of the mother-bud neck. The unstable Axl2/Bud10p disappears from the bud side of the mother-bud neck. 4, After cytokinesis, only mother cells inherit a patch of Axl2/Bud10p. The mother cell initiates bud formation adjacent to the residual patch of Axl2/Bud10p. 5, The daughter cell initiates bud formation using bipolar information, since it lacks a residual patch of Axl2/Bud10p. The residual patch of Axl2/Bud10p disappears from the mother cell (hatched rectangles).](JCB9902007.f8){#F8}
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